EAU 2013 - Programme Book - YouMed

ESU Courses
ESU Courses, 17 March
340 Programme Book
ESU Course 17
12.00 - 14.00 Management and outcome in invasive and locally advanced bladder
cancer
Orange Hall 2 - Level N-1
Chair: A. Alcaraz, Barcelona (ES)
Cystectomy in the management of bladder invasive and locally advanced bladder cancer
A. Alcaraz, Barcelona (ES)
Case discussion on cystectomy in the management of bladder invasive and locally advanced bladder cancer
B. Malavaud, Toulouse (FR)
Bladder sparing approaches to muscle invasive bladder cancer
A. Alcaraz, Barcelona (ES)
Case discussion on bladder sparing approaches to muscle invasive bladder cancer
B. Malavaud, Toulouse (FR)
Cytotoxic chemotherapy in bladder cancer: Neoadjuvant and adjuvant setting and treatment of metastatic
disease
B. Malavaud, Toulouse (FR)
Aims and objectives
Bladder cancer is the second most common oncological malignancy in Europe. Invasive and locally advanced
bladder tumour is the urological malignancy with the highest mortality.
The course will begin with the definition of the disease and different prognostic factors. Among
prognosticators of outcome will be discussed the role of early cystectomy in T1 patients with poor prognosis
indicators and the limitations of cystectomy in elderly and poor performance status patients. The course will
continue with the discussion of the different treatment options. Rationale for considering cystectomy as gold
standard, as well as a clear definition of multidisciplinary strategies for bladder sparing treatments with
special emphasis in patient selection and potential limitations will be discussed. Finally, the role of systemic
chemotherapy in the neoadjuvant and adjuvant to cystectomy setting will be presented, as well as in the
treatment of metastatic disease.
Specially recommended for elder residents and young urologists starting their career in the field of urooncology.
Also experienced uro-oncological surgeons will benefit from this course through an update,
focused on clinical issues and a practical approach.
At the conclusion of this course, the participants should get better insights in terms of:
- Stratifying the patients with invasive and locally advanced bladder cancer in different groups of risk.
- Understanding the rationales outcome and limitations of cystectomy and bladder sparing treatments.
- Defining the current role of neoadjuvant and adjuvant chemotherapy for invasive and locally advanced
bladder cancer.
- Measuring the benefits of systemic chemotherapy in terms of progression free survival and overall
survival.